Tamura Hiroto, Hosokawa Shinobu, Takahashi Takefumi, Kishi Koichi
Cardiology, Tokushima Red Cross Hospital, Tokushima, JPN.
Cureus. 2023 Feb 10;15(2):e34846. doi: 10.7759/cureus.34846. eCollection 2023 Feb.
Pulmonary endarterectomy (PEA) is the standard treatment for chronic thromboembolic pulmonary hypertension (CTEPH). However, repeating surgery in recurrent cases is generally deemed high-risk. Balloon pulmonary angioplasty (BPA), an alternative treatment for organized thrombotic lesions of the peripheral pulmonary artery, has also shown a good prognosis in cases of inoperable CTEPH. Here, we report the case of a 65-year-old woman who presented with dyspnea. She had been admitted to our hospital in 2015 and diagnosed with University of San Diego (USD)-California classification CTEPH of level II. PEA had been performed, which resolved her respiratory discomfort, and her WHO functional class had improved from IV to I. Post-surgery pulmonary angiography had shown several residual lesions; nonetheless, pulmonary hypertension had not been noted, and the patient had not experienced dyspnea thereafter. We had decided to continue medical therapy; however, the patient stopped taking anticoagulation and pulmonary vasodilators due to the absence of symptoms. In 2021, dyspnea recurred, and she was hospitalized for examination. Chest radiography showed no cardiomegaly, and heart failure and tricuspid regurgitation were absent on echocardiography. The six-minute walk test distance was 565 m, and the lowest oxygen saturation during the test was 92%. Right heart catheterization demonstrated a mean pulmonary arterial pressure (PAP) of 15 mmHg without pulmonary hypertension; however, pulmonary angiography showed new organized thrombotic lesions in the left segments of the lower lobe. Based on the advancement of the lesions, we speculated that they were the cause of the symptoms even without concurrent pulmonary hypertension. Therefore, we performed two additional BPA procedures. Subsequently, the mean PAP decreased further to 13 mmHg. The patient's symptoms improved, the six-minute walk test distance increased to 656 m, and the WHO functional class returned to I. In conclusion, BPA for recurrent lesions after surgery for CTEPH can improve the patient's symptoms and exercise tolerance.
肺动脉内膜剥脱术(PEA)是慢性血栓栓塞性肺动脉高压(CTEPH)的标准治疗方法。然而,复发病例再次手术通常被认为风险很高。球囊肺动脉血管成形术(BPA)是外周肺动脉机化血栓性病变的一种替代治疗方法,在无法手术的CTEPH病例中也显示出良好的预后。在此,我们报告一例65岁女性出现呼吸困难的病例。她于2015年入住我院,被诊断为加利福尼亚大学圣地亚哥分校(USD)II级CTEPH。已进行PEA,缓解了她的呼吸不适,其世界卫生组织功能分级从IV级改善到I级。术后肺血管造影显示有几处残留病变;尽管如此,未发现肺动脉高压,此后患者也未出现呼吸困难。我们决定继续药物治疗;然而,由于无症状,患者停止服用抗凝药和肺血管扩张剂。2021年,呼吸困难复发,她因检查住院。胸部X线检查未显示心脏扩大,超声心动图未发现心力衰竭和三尖瓣反流。六分钟步行试验距离为565米,试验期间最低血氧饱和度为92%。右心导管检查显示平均肺动脉压(PAP)为15 mmHg,无肺动脉高压;然而,肺血管造影显示下叶左段有新的机化血栓性病变。基于病变的进展,我们推测即使没有并发肺动脉高压,这些病变也是症状的原因。因此,我们又进行了两次BPA手术。随后,平均PAP进一步降至13 mmHg。患者症状改善,六分钟步行试验距离增加到656米,世界卫生组织功能分级恢复到I级。总之,CTEPH手术后复发病变的BPA治疗可改善患者症状和运动耐量。